A case of fabry cardiomyopathy.

Korean Circulation Journal
Jong Chun NahChuwa Tei

Abstract

In the absence of hypertension, hypertrophic cardiomyopathy is the most common cause of left ventricular hypertrophy (LVH). However, it has been reported that up to 3% of males with unexplained LVH have Fabry disease, an X-linked disorder of glycophospholipid metabolism that is due to a deficiency in the lysosomal enzyme alpha-galactosidase A (alpha-Gal A). A 44-year-old man was admitted to our hospital with palpitations. He had a history of chronic renal failure diagnosed at age 33 followed by kidney transplantation performed at our institution 2 years later, as well as long-standing hypohidrosis. His medications included prednisolone (5 mg daily), mycophenolate mofetil (1,000 mg, bid), and cyclosporine (150 mg, bid). On hospital day two, an echocardiogram demonstrated increased left ventricular wall thickness (septal wall thickness of 28 mm, posterior wall thickness of 20 mm). Diastolic dysfunction was noted on transmitral flow patterns and tissue Doppler imaging. The patient was found to have low plasma alpha-Gal A activity. A previously reported H46R missense mutation was detected in his alpha-Gal A gene and the patient was subsequently diagnosed with Fabry disease.

References

Feb 7, 1991·The New England Journal of Medicine·W von ScheidtR J Desnick
Aug 3, 1995·The New England Journal of Medicine·S NakaoH Sakuraba
May 29, 2000·American Heart Journal·A LinhartM Aschermann
Jun 2, 2000·Seminars in Dialysis·S Hariharan
Jun 21, 2001·JAMA : the Journal of the American Medical Association·R SchiffmannR O Brady
Jul 7, 2001·The New England Journal of Medicine·C M EngUNKNOWN International Collaborative Fabry Disease Study Group
Sep 20, 2005·The American Journal of Cardiology·Jaymin S ShahPerry M Elliott
Nov 14, 2006·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Marek JastrzebskiKalina Kawecka-Jaszcz
Dec 21, 2006·Annals of Internal Medicine·Maryam BanikazemiUNKNOWN Fabry Disease Clinical Trial Study Group
Jan 16, 2007·The American Journal of Cardiology·Makoto KawanoChuwa Tei
Nov 21, 2007·Current Opinion in Pediatrics·T Andrew BurrowGregory A Grabowski

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme replacement therapy
biopsy

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.